US3731683A - Bandage for the controlled metering of topical drugs to the skin - Google Patents

Bandage for the controlled metering of topical drugs to the skin Download PDF

Info

Publication number
US3731683A
US3731683A US3731683DA US3731683A US 3731683 A US3731683 A US 3731683A US 3731683D A US3731683D A US 3731683DA US 3731683 A US3731683 A US 3731683A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
drug
bandage
adhesive
material
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
A Zaffaroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Abstract

Bandage for the topical administration of controlled therapeutically effective quantities of topically active drugs has a backing member, a pressure-sensitive adhesive, and a reservoir layer containing a topically active drug confined within a wall member. The wall member is formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug through the wall to the skin at a controlled and predetermined rate over a period of time.

Description

United States Patent 91 Zalfaroni 51 *May 8,1973

[54) BANDAGE FOR THE CONTROLLED METERING OF TOPICAL DRUGS TO THE SKIN [75] Inventor: Alejandro Zafiaroni, Atherton,

Calif.

[73] Assignee: Alza Corporation Notice: The portion of the term of this patent subsequent to Aug. 10, 1988, has been disclaimed.

[22] Filed: June 4, 1971 [21] Appl. No.: 150,085

Related US. Application Data [63] Continuation-impart of Ser. No. 136,981, April 23,

[52] US. Cl. ..l28/268, 128/156, 424/28 [51] Int. Cl. ..A6lf 7/02 [58] Field of Search ..l28/260, 268, 156,

[56] References Cited UNITED STATES PATENTS 3,339,546 9/1967 Chen ..l28/268 X 3,444,858 5/1969 Russell ..l28/268 X 3,536,809 10/1970 Applczweig ..424l28 3,551,556 12/1970 Kliment et al. ..424 22 3,598,122 3 1971 Zaffaroni ..l28/268 3,598,123 8/1971 Zaffaroni .....l28/268 3,632,740 1 1972 Robinson et a1 ..424 28 Primary Examiner-Charles F. Rosenbaum Attorney-Steven D. Goldby, Edward L. Mandell and Paul L. Sabatine 57 ABSTRACT Bandage for the topical administration of controlled therapeutically effective quantities of topically active drugs has a backing member, a pressure-sensitive adhesive, and a reservoir layer containing a topically active drug confined within a wall member. The wall member is formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug through the wall to the skin at a controlled and predetermined rate over a period of time.

14 Claims, 5 Drawing Figures BANDAGE FOR THE CONTROLLED METERING OF TOPICAL DRUGS TO THE SKIN RELATED APPLICATIONS This application is a continuation-in-part of Ser. No. 136,981, filed Apr. 23, 1971, (Docket No. LR. 165A- CIP; Dl), entitled Therapeutic Adhesive Tape, of Alejandro Zaffaroni.

BACKGROUND OF THE INVENTION This invention relates to a device for the administration of drugs and more particularly to a medical bandage for the predetermined controlled metering of the flow of topically active drugs to the skin over a period of time. Topically active drugs, as that term is used in this specification and the appended claims, are agents which primarily cause a pharmacological or physiological response at or near the site of their application. They are to be distinguished from systemically active drugs which are transported from their site of application by the recipients circulatory system or lymphatic system, to cause a pharmacologic or physiologic response at a remote site in the body.

A large number of locally acting drugs are available to treat skin disorders or other conditions which manifest themselves in a manner such that they are susceptible to treatment via the skin. These drugs can be broadly classified as astringents, irritants, sclerosing agents, caustics, melanizing and demelanizing agents, keratolytics, mucolytics, antibacterials, anti-fungals, anti-inflammatories, antiporasitics, antiperspirants and deodorants, and the like. These drugs are conventionally topically administered to the skin with the active agent carried in the form of ointments, creams, salves, liniments, powders, dressings, and the like. The popularity of these types of formulations resides in the fact that it is quite easy to topically apply the agent to the skin in this manner. In most cases, however, it is not possible to determine how much of the preparation has been taken up or effectively administered to the skin since only non-uniform levels of the agent are available. A further undesirable feature is the unsightliness of these formulations which often discourage patients from using them during their waking hours of the day when they are most likely to be seen by others. Further, the preparations are subject to rub off onto clothing, thus causing much inconvenience and annoyance to the user.

In order to obviate some of these undesirable effects, it has been proposed to provide medicinal bandages wherein the absorbent portion to be applied to the area to be treated is further provided with drug material adhered thereto. The advantage of a bandage construction of this type, of course, resides in the elimination of the intermediate step of applying the drug. A further advantage is realized by the elimination of the possibility that the drug which is often in a liquid formulation will be lost by run-off or leakage. A significant disadvantage, however, also exists with these prior art devices for the administration of topically active drugs in that the amount of medication applied to the affected areas cannot be accurately controlled, nor is there any assurance that sufficient medication will be available for the duration of periods that it is required.

It has also been proposed to admix certain topical drugs in the adhesive materials of bandages to treat various skin conditions with improved convenience; see for example British Pat. No. l,2l6,908. Further, it is known that medicaments can be incorporated into certain types of crushable microcapsules which are then incorporated in bandages; see for example Goldfarb US. Pat. No. 3,464,4l3. The microcapsules, however, merely function as drug carriers releasing the drug by rupture of the microcapsules. Therefore, these bandages are not suitable for continuously controlling the dosage of the drug administered, which is a most desirable objective of drug therapy.

SUMMARY OF THE INVENTION Accordingly, an object of this invention is to provide a bandage for the improved continuous administration of predetermined controlled quantities of topically active drugs to the skin over a period of time.

In accomplishing these objects, this invention in its broadest aspects resides in a medicated bandage for the continuous administration of controlled quantities of topically active drugs to the skin of a patient by direct application to the affected skin area. The bandage is comprised of a laminate of: l a backing member defining one face surface of the bandage; (2) a pressure-sensitive adhesive adapted for contact with the skin or mucosa, the external surface of said pressuresensitive adhesive defining the other face surface of the bandage and disposed between the face surfaces defined by l) and (2); (3) at least one reservoir comprised of a topically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of drug from the said reservoir to the skin or mucosa at a controlled and predetermined rate over a prolonged period of time.

The termreservoir as used herein refers both to microcapsules as well as distinct reservoir compartments or matrix layers.

An embodiment of the invention described above resides in a bandage comprised of a laminate of: (l) a backing member; bearing (2) a discrete middle reservoir layer containing a topically active therapeutic agent confined within a wall member, said wall member being formed from drug release rate controlling material permeable to the passage of agent, to continuously meter the flow of a therapeutically effective amount of the agent to the skin from the reservoir at a controlled and predetermined rate over a period of time; and (3) a pressure-sensitive adhesive surface adapted for contact with the skin and positioned on one wall of the reservoir remote from the backing member.

Another aspect of this invention resides in a bandage as described immediately above including a solubility membrane interposed between the wall of the reservoir and the pressure-sensitive adhesive layer.

Still, another embodiment of this invention resides in a medicated adhesive bandage comprising a laminate of: l a backing member; bearing (2)'a pressure-sensitive adhesive on one surface thereof adapted for contact with the skin, said pressure-sensitive adhesive having distributed therethrough, (3) a plurality of discrete microcapsules, each of which microcapsules comprise a topically active therapeutic agent confined within a wall member, the wall member being formed from drug release rate controlling material, to continuously meter the flow of a therapeutically effective amount of the agent to the skin from the microcapsules at a controlled and predetermined rate over a period of time.

Other objects, features and advantages of the invention will become more apparent from the following description when taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:

FIG. 1 is a perspective view of the medical adhesive bandage of the invention wherein the topically active agent is microencapsulated with a material permeable to the passage of those agents and the microcapsules are uniformly distributed throughout the pressure-sensitive adhesive coating;

FIG. 2 is a cross-sectional view of the bandage of the invention shown in FIG. 1;

FIG. 3 is a cross-sectional view of another embodiment of the invention wherein the topically active agent is uniformly distributed throughout a matrix of material permeable to the passage of those agents and the material is laminated to a backing member. The matrix material which acts as a reservoir for the agent bears a coating of the pressure-sensitive adhesive thereon;

FIG. 4 is a cross-sectional view of still another embodiment of the invention wherein the adhesive bandage of the invention is comprised of a backing member having a reservoir on one surface thereof of topically active agent uniformly distributed throughout a matrix of material permeable to passage of agent, and on the surface of the reservoir remote from the backing member bearing a pressure-sensitive adhesive coating. A solubility membrane is interposed between the reservoir layer and the pressure-sensitive adhesive coating;

FIG. 5 is a cross-sectional view of another embodiment of the invention wherein the reservoir laminated to the backing member is a hollow container permeable to passage of agent and having the agent confined within the interior chamber thereof.

DETAILED DESCRIPTION OF THE INVENTION In accordance with this invention there is provided a v medicated bandage containing a topically active drug therein for the predetermined controlled metering of the flow of topically active drugs to the skin over a period of time.

FIG. 1 illustrates an adhesive tape 10 of the invention including a backing member 11 bearing a pressure-sensitive adhesive coating 12 on one surface thereof. Ad-. hesive coating 12 has uniformly distributed therethrough microcapsules 13 of topically active agent encapsulated with a material permeable to passage of the drug.

Materials used to encapsulate the drug and form the microcapsules to be distributed throughout the adhependent on the particular drug used in the bandage. By varying the encapsulating material and the wall thickness, the dosage rate per area of bandage can be controlled and movement of drug to the adhesive regulated.

Suitable materials for use in encapsulating the drug include hydrophobic polymers such as polyvinylchloride either unplasticized or plasticized with long-chain fatty amides or other plasticizer; plasticized nylon; unplasticized soft nylon; silicone rubber; polyethylene, and polyethylene terephthalate; and hydrophilic polymers such as esters of acrylic and methacrylic acid (as described in US. Pat. Nos. 2,976,576 and 3,220,960 and Belgian Pat. No. 701,813); modified collagen; cross-linked hydrophilic polyether gels (as described in US. Pat. No. 3,419,006); cross-linked polyvinylalcohol; and crosslinked partially hydrolyzed polyvinylacetate.

To provide the microcapsules, the encapsulating material can be uniformly impregnated with the drug to form microcapsules which are a matrix having the drug distributed therethrough. Alternatively, particles of drug can be encapsulated with thin coatings of the encapsulating material to form microcapsules having an interior chamber containing the drug. If desired, parti cles of a matrix, such as starch, gum acadia, gum tragacanth, and polyvinylchloride, can be impregnated with the drug and encapsulated with other materials such as the encapsulating materials previously described which function as a solubility membrane to .meter the flow of drug to the adhesives; use of a matrix and a different solubility membrane coating can slow the passage of the drug from the microcapsules which is desirable with drugs that are released too rapidly from available encapsulating materials.

Airy of the encapsulation or impregnation techniques known in the art can be used to prepare the microcapsules to be incorporated into the pressure-sensitive adhesive in accord with the embodiment of FIGS. 1 and 2. Thus, the drug can be added to the encapsulating material in liquid form and uniformly distributed therethrough by mixing and subsequently converting to a solid by curing or cooling; or solid encapsulating material can be impregnated with a drug by immersion in a bath of the drug to diffuse into the material. Subsequently, the solid material can be reduced to fine microcapsules by grinding, each of the microcapsules comprising drug coated with and distributed throughout the encapsulating material. Alternatively, fineparticles of the drug can be encapsulated with the coating. One suitable technique comprises suspending dry particles of the drug in an air stream and contacting that stream with a stream containing the encapsulating material to coat the drug particles. Usually, the microcapsules have an average particle size of from I to l ,000 microns, although this is not critical to the invention.

Further embodiments of the adhesive bandage of the invention are illustrated in FIGS. 3, 4 and 5. As illustrated in FIG. 3, adhesive bandage 20 of the invention is comprised of topically active agent 24 uniformly distributed in a reservoir 22 which is a polymeric matrix material. The matrix material is laminated to backing member 21 and bears a pressure-sensitive adhesive coating 23 thereon. The polymeric matrix material has a release rate for the particular drug used which continuously controls the releasing drug.

FIG. 4 illustrates a further modified form of the invention wherein the adhesive bandage 30 of the invention is comprised of a backing member 21 having a reservoir 32 on one surface thereof. A solubility member 35 is interposed between the reservoir 32 and a pressure-sensitive adhesive coating 23. Topically active agent 24 is confined in polymeric matrix material 32 which acts as the reservoir for the drug.

FIG. 5 illustrates a further form of the bandage 40 including a backing member 21 and a reservoir 42 in the form of a hollow container having an interior chamber 43 containing topically active agent 34. Wall 45 of reservoir 42, remote from backing member 21, is permeable to passage of drug 34, as by diffusion, to meter the flow of drug to pressure-sensitive adhesive layer 23 on the outer surface thereof. This form of the bandage is less preferred since it cannot conveniently be cut to fit precisely the size of skin lesions to which applied. However, it is satisfactory for application to large areas of skin.

Suitable materials for forming the reservoir, whether of the matrix or hollow container type, are those materials permeable to passage of the drug previously described as suitable encapsulating materials. The reservoir can be formed by molding into the form of a hollow container with the drug trapped therein. Alternatively, the reservoir can bein the form of an envelope formed from sheets of polymeric material permeable to passage of the drug and enclosing the drug. While the walls of the reservoir can be of any convenient thickness, usually they have a thickness of from 0.01 to 7 millimeters. When the reservoir comprises a matrix with the drug distributed therethrough, it can be prepared by adding the drug to the matrix material in liquid form or solvent solution form and subsequently converting the matrix to a solid by curing, cooling or evaporation of solvent.

Thus, the reservoir of the bandage is a hollow drug container or a solid matrix. Drug is metered from the reservoir to the adhesive layer, at a rate controlled by the composition and thickness of the reservoir or of the reservoir wall. From the adhesive layer, drug is directly transmitted to the skin to which the bandage is applied.

In the embodiment of the invention illustrated in FIG. 4, metering of the drug from the reservoir to the adhesive is further controlled by interposing a further solubility membrane therebetween. The solubility membrane is formed ofa material in which the drug is soluble and capable of diffusing through. Any of the materials previously mentioned for use in microencapsulation may be used as the solubility membrane. Of course, in each instance, the solubility membrane will have different characteristics than the reservoir wall of the particular device. This use of a pair of solubility membranes, that is, the reservoir wall and the further solubility membrane, allows for precise metering of drug to the adhesive layer; for the thickness and composition of both membranes can be varied to provide for wide range of dosage levels for a given area of bandage. It will be appreciated that this solubility membrane can be used with either the matrix or container type of reservoir.

In practicing this invention one can employ a wide variety of topically active drugs consistent with their known dosages and uses. Suitable drugs include, without limitation: Antiperspirants, e.g. aluminum chloride; Deodorants, e.g. hexachlorophene, methylbenzethonium chloride; Astringents, e.g. tannic acid; Irritants, e.g. methyl salicylate, camphor, cantharidin; Keratolytics, e.g. benzoic acid, salicylic acid, resorcinol, iodochlorhydroxyguin; Antifungal Agents such as tolnaftate, griseofulvin, nystatin and amphotericin; Anti-Inflammatory Agents, such as corticosteroids, e.g. hydrocortisone, hydrocortisone acetate, prednisolone, methylprednisolone, triamcinolone acetonide, fluidrocortisone, flurandrenolone, fiumethasone, dexamethasone sodium phosphate, bethamethasone valerate, fluocinolone acetonide; fluorometholone; and pramoxine HCl; and Antibacterial Agents, such as bacitracin, neomycin, erythromycin, tetracycline HCI, chlortetracycline HCI, chloramphenicole, oxytetracycline, polymyxin B, nitrofurazone, mafenide (aamino-p-toluenesulfonamide), hexachlorophene, benzalkonium chloride, cetalkonium chloride, methylbenzethonium chloride, and neomycin sulfate.

In addition to the aforementioned drugs, simple pharmacologically acceptable derivatives of the drugs, such as ethers, esters, amides, acetals, salts, etc., or formulations of these drugs, having the desired polymeric permeability or transport properties can be prepared and used in practicing the invention. Drugs mentioned above can be used alone or in combination with others and each other.

The amount of topically active agent to be incorporated in the bandage to obtain the desired therapeutic effect will vary depending upon the desired dosage, the permeability of the polymeric materials of the bandage which are employed to the particular agent to be used, and the length of time the bandage is to remain on the skin. The effective rate or release of the active agent to the skin can be in the range of from 0.5 to 1,000 micrograms per square centimeter of bandage per day. The exact amount will depend on the desired dosage as well as the area of the skin to be treated. These effective rates of release of active agent to the skin can be obtained by altering the permeability and thickness of the release rate controlling barrier. In the case of the microencapsulated active agent, the release rate can also be controlled by varying the number of microcapsules present in a given volume of the matrix of the device. This is a particular desirable feature of this aspect of the invention. Additionally, the duration of action of the device can be altered by controlling the amount of active agent initially incorporated consistent with the release rate. Further, the release rate of drug as well as the duration of release of the drug from the device can be predetermined to be in consonance with the optimum therapeutic values. Once this dosage level in micrograms per square centimeter of bandage has been determined, the total amount of drug to be incorporated in the bandage can be established by obtaining the release rate of the agent in the particular material or materials which are to be used.

Those skilled in the art can readily determine the rate of permeation of agent through a polymeric material or selected combinations of polymeric materials. One method that has been found to be eminently well suited is to cast or hot press a film of the material to a thickness in the range of 2 to 60 mils. The film is used as a barrier between a rapidly stirred (e.g. 150 r.p.m.) saturated solution of the drug containing excess solid drug (or a concentrated solution of the drug) and a rapidly stirred solvent bath, both maintained at :constant temperature (typically 37 C). Samples are periodically withdrawing from the solvent bath and analyzed for drug concentration. By plotting drug concentration in the solvent bath versus time, the permeability constant P of the membrane is determined by the Ficks First Law of Diffusion.

Slope of plot Q, Q /t z =p (AC/h) I wherein Q' cumulative amount of drug in solvent in micrograms at t Q cumulative amount of drug in solvent in microgram at 1 t, elapsed time to first sample i.e. Q

t elapsed time to second sample i.e. Q

A area of membrane in cm C saturation concentration of drug in solution h thickness of membrane in cm.

By determining the slop of the plot i.e. Q Q /t t and solving the equation using the known or measured values of A, C, and h, the permeability P constant in cm /time of the material or membrane for a given compound is readily determined. Of course, this permeability constant is an inherent characteristic of the material for a given compound.

Using the above technique, the permeability constant P of hydrocortisone from isotonic solution through different membranes into isotonic solution at 37 C was found to be:

Membrane Permeability Constant (cm lhr) Silicone Rubber 835 Aromatic Polyamide 2 Down Corning- HH07l7 2 Allied Chemical Capran Using the abovetechnique and data, the permeability constant P for a select membrane and drug can be determined. These data can then be employed to design a device of the invention to release the agent to the skin in the desired dosage range. Similarly, this experimental procedure or others known to those skilled in the art can be used to determine release rates for the suitable polymeric materials as above disclosed in order to design the bandage of this invention.

Other methods of the determining passage of drugs by diffusion through drug permeable polymeric material are available. See Dziuk, P. J. and Cook, 3., Passage of Steroids Through Silicone Rubbers, Endocrinology, 78:208, 1966; U.S. Pat. No. 3,279,996; Folkman and Edmonds, Circulation Research 10:632, l962; Folkman and Long, J. Surg. Res. 432139, 1964; Powers, J. Parasitology 51 :53 April, 1965), No. 2 Section 2.

Any of the well-known dermatologically acceptable permeable pressure-sensitive adhesives which permit drug migration can be used in practicing this invention. Exemplary adhesives include acrylic or methacrylic resins such as polymers of esters of acrylic or methacrylic acid with alcohols such as n-butanol, npentanol, isopentanol, 2-methyl butanol, l-methyl butanol, l-methyl pentanol, 2-methyl pentanol, 3-methyl pentanol, 2-ethyl butanol, isooctanol, n-decanol, or ndodecanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, acrylamide, methacrylamide, N-alkoxymethyl acrylamides, N-alkoxymethyl methacrylamides, N-tert. butylacrylamide, itaconic acid, vinylacetate, N- branched alkyl maleamic acids wherein the alkyl group has l0 to 24 carbon atoms, glycol diacrylates, or mixtures of these; natural or synthetic rubbers such as silicone rubber, styrene-butadiene, butyl-ether, neoprene, polyisobutylene, polybutadiene, and polyisoprene; polyurethane elastomers; vinyl polymers, such as polyvinylalcohol, polyvinyl ethers, polyvinyl pyrrolidone, and polyvinylacetate; ureaformaldehyde resins; phenolformaldehyde resins; resorcinol formaldehyde resins; cellulose derivatives such as ethyl cellulose, methyl cellulose, nitrocellulose, cellulose acetatebutyrate, and carboxymethyl cellulose; and natural gums such as guar, acacia, pectins, starch, dextrin, albumin, gelatin, casein, etc. The adhesives may be compounded with tackifiers and stabilizers as is well known in the art.

Various occlusive and non-occlusive, flexible or nonflexible backing members can be used inthe adhesive bandageof the invention. Suitable backings include cellophane, cellulose acetate, ethylcellulose plasticized vinylacetate-vinylchloride copolymers, polyethylene terephthalate, nylon, polyethylene,

polypropylene, polyvinylidenechloride, paper, cloth, and aluminum foil. Preferably, a flexible occlusive backing is employed to conform to the shape of the body member to which the adhesive tape is applied and to enhance administration of the agent to the skin.

To prevent passage of the drug away from the exposed surface of the pressure-sensitive adhesive prior to use, the adhesive surface of the tape generally is covered with a protective release film or foil, such as waxed paper. Alternatively, the exposed rear surface of the backing member can be coated with a low-adhesion backsize and the bandage rolled about itself. To enhance stability of the active compounds, the therapeutic bandage usually is packaged between hermetically sealed polyethylene terephthalate films under an inert atmosphere, such as gaseous nitrogen.

To use the adhesive bandage of the invention, it is applied directly to skin, to release a therapeutically effective amount of the agent to the affected area. By use of this invention, one ensures that an accurately measured quantity of the active drug is available when the bandage is applied to the skin.

The following examples will serve to illustrate the invention without in any way being limiting thereon.

EXAMPLE I Z-hydroxyethyl methacrylate (100 grams) is diluted with water (100 grams) and mixed with tertiary butyl peroctoate (0.20 gram). Ethylene glycol dimethacrylate (0.20 gram) is added along with 4 grams of sodium bicarbonate as a foaming agent. The mixture is heated to C under an atmosphere of nitrogen and the resulting solid, friable polymeric foam is ground into fine powder of 20 micron average particle size. The polymeric powder (10 grams) is mixed with neomycin (2 grams) dissolved in a mixture of ethyl alcohol: water (50:50) and the resultant mixture placed on a mechanical roller until the polymeric powder has absorbed the drug. The solution is then filtered.

The resulting microcapsules of neomycin are mixed with 100 grams of a 22 percent solution in hexane: isopropylacetate (70:30) of a viscoelastic copolymer of isooctyl acrylate and acrylic acid (94:6) adhesive to uniformly distribute the microcapsules throughout the adhesive solution. The resulting slurry is coated onto a cellophane sheet 10 centimeters in width by 100 centimeters in length and the solvent removed by evaporation from the coated film.

When applied to the infected skin area of a subject, the resulting bandage is effective to control the continuous administration of a daily therapeutically effective dosage of neomycin to the skin.

EXAMPLE ll Liquid dimethyl silicone polymeric rubber 100 grams, Dow-Corning Silastic) is mixed with 5 grams of nitrofurazone. After uniformly mixing the drug with unvulcanized silicone rubber, 0.5 gram of stannous octoate catalyst is added and the rubber cured at room temperature. The resulting silicone rubber body is reduced to an average particle size of 100 microns. Pressure-sensitive adhesive composition is prepared by adding to 100 milliliters of hexane the following:

grams of polyvinylethyl ether (reduced visosity= 5.0 i 0.5)

4 grams of polyvinylethylether (reduced viscosity= 0.3 i 0. l

4 grams of glycerol ester of hydrogenated rosin and 2 grams polyethylene glycol 400 Ten grams of the resulting nitrofurazone capsules are mixed with pressure-sensitive adhesive prepared above to uniformly distribute the microcapsules throughout the adhesive. Immediately thereafter, the adhesive mixture is coated onto one surface of a 1,000 square centimeter Mylar sheet. The resulting bandage can be used for control of skin infections.

EXAMPLE lll Ten milligrams of betamethasone is placed on a sheet of dimethyl silicone rubber having a thickness of 0.13 millimeters. The sheet is folded to provide a surface area of 100 square centimeters on each face and the flaps sealed with silicone adhesive to provide a thin envelope containing the drug.

Pressure-sensitive adhesive is prepared by mixing together, 90 grams of polyacrylate solution (ethylacetate: hexane/5:1) containing percent nonvolatile matter, (obtained by the catalytic polymerization of isoamylacrylatc and acrylic acid in the ratio of 95:5 in ethylacetatc and then diluting with hexane), 5 grams polyvinylethylether (reduced viscosity= 0.3 i 0.1), l gram castor oil (USP) and 4 grams polyethyleneglycol 400.

One face surface of the envelope is bonded to a sheet of cellophane while the other is coated with adhesive prepared above to a thickness of2 millimeters. The adhesive face surface of the bandage has an area of 100 square centimeters. The bandage is effective to release a therapeutically effective daily dosage of the drug when applied to the skin for control of psoriasis.

Thus, this invention provides a reliable and easy to use device for administering topically active drugs directly to the skin. Uncertainties resulting from topical application of these agents, from creams and solutions, are not encountered; and a precisely determined amount of the drug is applied in a controlled manner.

Although the product of this invention has been referred to as an adhesive bandage, those skilled in the art will appreciate that the term adhesive bandage as used herein includes any product having a backing member and a pressure-sensitive adhesive face surface. Such products can be provided in various sizes and configurations, including tapes, bandages, sheets, plasters, and the like.

While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, it will be understood that various omissions and substitutions and changes in the form and details of the adhesive tape illustrated may be made by those skilled in the art without departing from the spirit of the invention. It is the intention, therefore, to be limited only as indicated by the scope of the following claims.

What is claimed is:

l. A medical bandage for the continuous administration to the skin or mucosa of controlled quantities of topically active drugs over a prolonged period of time, said bandage comprising a laminate of (1) a backing member defining one face surface of the bandage; (2) a pressure-sensitive adhesive adapted for contact with the skin or mucosa, the external surface of said pressure-sensitive adhesive defining the other face surface of the bandage and disposed between the face surfaces defined by (l) and (2); (3) at least one reservoir comprised of a topically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of drug from the said reservoir to the skin or mucosa at a controlled and predetermined rate over a prolonged period of time.

2. The medical bandage of claim 1, wherein said bandage comprises a laminate of: (l) a backing member; bearing (2) a pressure-sensitive adhesive on one surface thereof adapted for contact with the skin, said pressure-sensitive adhesive having distributed therethrough; (3) a plurality of discrete microcapsules, each of which microcapsules comprises a topically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug in the skin through the wall of said microcapsules at a controlled and predetermined rate over a period of time.

3. The bandage as defined by claim 2, wherein each of said microcapsules (3) is comprised of topically active drug formulation microencapsulated with the drug release rate controlling material.

4. The bandage as defined by claim 2, wherein each of said microcapsules (3) is comprised of a matrix of the drug release rate controlling wall material, said matrix having the topically active drug formulation distributed therethrough.

5. The bandage as defined by claim 2, wherein the drug formulation includes a pharmacologically acceptable solvent.

6. The medical bandage of claim 1, wherein said bandage comprises a laminate of: (l) a backing member; bearing (2) a discrete, middle reservoir layer, which reservoir layer is comprised of topically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug to the skin through the wall at a controlled and predetermined rate over a period of time; and (3) a pressure-sensitive adhesive adapted for contact with the skin and carried by the reservoir remote from the backing member.

7. The bandage as defined by claim 6, wherein the reservoir layer (2) is comprised of a walled container having an interior chamber containing the topically active drug formulation.

8. The bandage as defined by claim 6, wherein the reservoir layer (2) is comprised of a matrix of the drug release rate controlling wall material, said matrix having the topically active drug formulation distributed therethrough.

9. The bandage as defined by claim 6, wherein the drug formulation includes a pharmacologically acceptable solvent.

10. The bandage as defined by claim 6, further comprising a solubility membrane (4) interposed between said reservoir layer (2) and said surface of pressuresensitive adhesive (3).

11. The bandage as defined by claim 2, wherein the rate release controlling material is silicone rubber.

12. The bandage as defined by claim 6, wherein the rate release controlling material is silicone rubber.

13. The bandage as defined by claim 2, wherein the rate release controlling material is a hydrophilic polymer of an ester of an olefinic acid.

14. The bandage as defined by claim 6, wherein the rate release controlling material is a hydrophilic polymer of an ester of an olefinic acid.

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,731, 3 Dated May 8l975 It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 3, lines 33, 34, and 35, "...agent, and on the surface of the reservoir remote from the backing member bearing a..." should read ...a ent, and bearing on the surface of the reservoir remote rom the backing member a.

Column 4, line 27, "acadia" should read -acacia-; Column 5, line 7, "member" should read --membrane--; Column 5, line 54, add after "and" and before "capable" the following: -through which the drug is-; same column and line, delete the word "through" after the word "diffusing"; Column 7, line 8, "withdrawing" should read --withdrawn-. I

' Signed and sealed this 17th day of September 1974.

(SEAL) Attest:

McCOY M. GIBSON JR. C. MARSHALL DANN Attesting Officer Commissioner of Patents USCOMM-DC 60376-P69 u 5. GOVERNMENT PRINTING OFFICE: I969 o-aes-aaa FORM O-1050 (10-69]

Claims (12)

  1. 2. The medical bandage of claim 1, wherein said bandage comprises a laminate of: (1) a backing member; bearing (2) a pressure-sensitive adhesive on one surface thereof adapted for contact with the skin, said pressure-sensitive adhesive having distributed therethrough; (3) a plurality of discrete microcapsules, each of which microcapsules comprises a topically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug in the skin through the wall of said microcapsules at a controlled and predetermined rate over a period of time.
  2. 3. The bandage as defined by claim 2, wherein each of said microcapsules (3) is comprised of topically active drug formulation microencapsulated with the drug release rate controlling material.
  3. 4. The bandage as defined by claim 2, wherein each of said microcapsules (3) is comprised of a matrix of the drug release rate controlling wall material, said matrix having the topically active drug formulation distributed therethrough.
  4. 5. The bandage as defined by claim 2, wherein the drug formulation includes a pharmacologically acceptable solvent.
  5. 6. The medical bandage of claim 1, wherein said bandage comprises a laminate of: (1) a backing member; bearing (2) a discrete, middle reservoir layer, which reservoir layer is comprised of topically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug to the skin through the wall at a controlled and predetermined rate over a period of time; and (3) a pressure-sensitive adhesive adapted for contact with the skin and carried by the reservoir remote from the backing member.
  6. 7. The bandage as defined by claim 6, wherein the reservoir layer (2) is comprised of a walled container having an interior chamber containing the topically active drug formulation.
  7. 8. The bandage as defined by claim 6, wherein the reservoir layer (2) is comprised of a matrix of the drug release rate controlling wall material, said matrix having the topically active drug formulation distributed therethrough.
  8. 9. The bandage as defined by claim 6, wherein the drug formulation includes a pharmacologically acceptable solvent.
  9. 10. The bandage as defined by claim 6, further comprising a solubility membrane (4) interposed between said reservoir layer (2) and said surface of pressure-sensitive adhesive (3). 11. The bandage as defined by claim 2, wherein the rate release controlling material is silicone rubber.
  10. 12. The bandage as defined by claim 6, wherein the rate release controlling material is silicone rubber.
  11. 13. The bandage as defined by claim 2, wherein the rate release controlling material is a hydrophilic polymer of an ester of an olefinic acid.
  12. 14. The bandage as defined by claim 6, wherein the rate release controlling material is a hydrophilic polymer of an ester of an olefinic acid.
US3731683A 1971-06-04 1971-06-04 Bandage for the controlled metering of topical drugs to the skin Expired - Lifetime US3731683A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15008571 true 1971-06-04 1971-06-04

Publications (1)

Publication Number Publication Date
US3731683A true US3731683A (en) 1973-05-08

Family

ID=22533069

Family Applications (1)

Application Number Title Priority Date Filing Date
US3731683A Expired - Lifetime US3731683A (en) 1971-06-04 1971-06-04 Bandage for the controlled metering of topical drugs to the skin

Country Status (1)

Country Link
US (1) US3731683A (en)

Cited By (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870041A (en) * 1973-08-16 1975-03-11 Btr Industries Ltd Surgical dressings
US3900027A (en) * 1974-01-02 1975-08-19 Pall Corp Process for preparing integral absorbent pad bandages and product
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
FR2368962A1 (en) * 1976-11-02 1978-05-26 Merck Patent Gmbh anti-bacterial dressing and process for its manufacture
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4226232A (en) * 1979-04-09 1980-10-07 Spenco Medical Corporation Wound dressing
US4289749A (en) * 1979-08-14 1981-09-15 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylpropanolamine
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4329333A (en) * 1980-11-24 1982-05-11 Arthur Barr Method for the oral treatment of dogs and other animals
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
US4340043A (en) * 1978-11-17 1982-07-20 Smith & Nephew Research Ltd. Adhesive-coated sheet material incorporating anti-bacterial substances
DE3208853A1 (en) * 1981-03-13 1982-09-23 Nitto Electric Ind Co A process for the preparation of a pharmaceutical preparation composite
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4390520A (en) * 1980-10-30 1983-06-28 Nitto Electric Industrial Co., Ltd. Antiphlogistic analgesic adhesive
US4455146A (en) * 1979-04-03 1984-06-19 Hisamitsu Pharmaceutical Co., Ltd. Novel plasters
WO1984002460A1 (en) * 1982-12-28 1984-07-05 Dermatec Ltd Sebum collection and monitoring means
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4594240A (en) * 1982-09-10 1986-06-10 Teikoku Seiyaku Kabushiki Kaisha Sheet-shape adhesive preparation
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4614787A (en) * 1984-11-13 1986-09-30 Thermedics, Inc. Drug dispensing wound dressing
US4631227A (en) * 1982-12-08 1986-12-23 Kenji Nakamura Toilet article
WO1987000042A1 (en) * 1985-07-02 1987-01-15 Rutgers, The State University Of New Jersey Transdermal verapamil delivery device
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
WO1987003477A1 (en) * 1985-12-12 1987-06-18 Flexcon Company, Inc. Transdermal methods and adhesives
EP0236266A1 (en) * 1986-02-14 1987-09-09 Ciba-Geigy Ag Dermal and transdermal therapeutic system having a discontinuous-pattern adhesive layer and method of manufacturing thereof
US4727868A (en) * 1984-11-13 1988-03-01 Thermedics, Inc. Anisotropic wound dressing
DE3629304A1 (en) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg A transdermal therapeutic system, its use and process for its manufacture
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4751133A (en) * 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
EP0273004A2 (en) * 1986-11-20 1988-06-29 Ciba-Geigy Ag User-activated therapeutical system
US4830854A (en) * 1987-12-18 1989-05-16 James B. Copelan Chemical splinter removal
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4844903A (en) * 1986-11-07 1989-07-04 Mepha Ag Process for the production of an adhesive plaster
USRE32991E (en) * 1984-11-13 1989-07-18 Thermedics, Inc. Drug dispensing wound dressing
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4880690A (en) * 1984-11-13 1989-11-14 Thermedics, Inc. Perfume patch
US4889720A (en) * 1986-09-01 1989-12-26 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form for use with tissues of the oral cavity
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4969871A (en) * 1989-02-15 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US4985016A (en) * 1989-02-15 1991-01-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4991574A (en) * 1987-07-22 1991-02-12 Dow Corning Corporation Surgical dressing
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5034386A (en) * 1986-01-31 1991-07-23 Whitby Research, Inc. Methods for administration using 1-substituted azacycloalkanes
US5035894A (en) * 1987-10-15 1991-07-30 Dow Corning Corporation Controlled release compositions and transdermal drug delivery device
US5045059A (en) * 1989-02-15 1991-09-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5173302A (en) * 1990-09-28 1992-12-22 Medtronic, Inc. Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5176915A (en) * 1989-03-14 1993-01-05 Lts Lohmann Plaster used as therapeutic system for the administration of active substances to the skin which exhibits a graduated active substance release, process for the production of the plaster and the use thereof
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5230896A (en) * 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
US5250028A (en) * 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US5268179A (en) * 1992-02-14 1993-12-07 Ciba-Geigy Corporation Ultrasonically sealed transdermal drug delivery systems
US5298257A (en) * 1987-05-01 1994-03-29 Elan Transdermal Limited Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5342623A (en) * 1986-09-12 1994-08-30 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5508039A (en) * 1991-10-18 1996-04-16 Alza Corporation Controlled transdermal administration of melatonin
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5643596A (en) * 1993-11-03 1997-07-01 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5747065A (en) * 1993-09-29 1998-05-05 Lee; Eun Soo Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5820876A (en) * 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5919478A (en) * 1993-06-25 1999-07-06 Alza Corporation Incorporating poly-N-vinyl amide in a transdermal system
WO1999040955A2 (en) * 1998-02-12 1999-08-19 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US6001390A (en) * 1995-06-07 1999-12-14 Alza Corporation Formulations for transdermal delivery of pergolide
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6117448A (en) * 1986-08-28 2000-09-12 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
US6126963A (en) * 1986-08-28 2000-10-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6183770B1 (en) * 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
US6300327B1 (en) 1991-11-08 2001-10-09 The University Of Southern California Compositions and methods for potentiation of neurotrophin activity
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6469227B1 (en) 1999-12-10 2002-10-22 Lectec Corporation Antipruritic patch
US6479073B1 (en) * 1996-10-07 2002-11-12 3M Innovative Properties Company Pressure sensitive adhesive articles and methods for preparing same
USRE37934E1 (en) 1986-08-28 2002-12-10 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US20030107149A1 (en) * 2001-10-12 2003-06-12 International Fluidics. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US6592892B1 (en) 1999-08-30 2003-07-15 Tepha, Inc. Flushable disposable polymeric products
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US20040209907A1 (en) * 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
US20040234585A1 (en) * 1998-12-18 2004-11-25 Gale Robert M. Transparent transdermal nicotine delivery devices
US20040234576A1 (en) * 2003-05-08 2004-11-25 Tepha, Inc., State Of Incorporation Delaware Polyhydroxyalkanoate medical textiles and fibers
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US20050002997A1 (en) * 2003-04-30 2005-01-06 Howard Stephen A. Tamper resistant transdermal dosage form
US20050025809A1 (en) * 2003-07-08 2005-02-03 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
US20050037055A1 (en) * 2002-04-11 2005-02-17 Monosolrx Llc. Polyethylene oxide-based films and drug delivery systems made therefrom
US20050048104A1 (en) * 1999-04-01 2005-03-03 Venkatraman Subramanian S. Transdermal drug delivery devices comprising a polyurethane drug reservoir
US20050065062A1 (en) * 2003-09-24 2005-03-24 3M Innovative Properties Company Method of formulating a pharmaceutical composition
US20050142475A1 (en) * 2003-12-30 2005-06-30 Moudry Ronald J. Dry toner comprising encapsulated pigment, methods and uses
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US20060009099A1 (en) * 2004-07-12 2006-01-12 Closure Medical Corporation Adhesive-containing wound closure device and method
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US20060058470A1 (en) * 2004-08-03 2006-03-16 Tepha, Inc. Non-curling polyhydroxyalkanoate sutures
US20060121103A1 (en) * 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
EP1674068A1 (en) 1996-02-19 2006-06-28 Acrux DDS Pty Ltd Dermal penetration enhancers and drug delivery systems involving same
US20060147493A1 (en) * 2002-07-22 2006-07-06 Yang Robert K Packaging and dispensing of rapid dissolve dosage form
US20060287659A1 (en) * 2003-08-22 2006-12-21 Tepha, Inc. Polyhydroxyalkanoate nerve regeneration devices
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
USRE39588E1 (en) 1987-11-09 2007-04-24 Alza Corporation Transdermal drug delivery device
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
US20070122455A1 (en) * 2001-10-12 2007-05-31 Monosolrx, Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070149731A1 (en) * 2001-10-12 2007-06-28 Monosolrx, Llc. PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
WO2007011763A3 (en) * 2005-07-15 2007-07-12 3M Innovative Properties Co Adhesive sheet and methods of use thereof
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US20070202245A1 (en) * 2004-04-08 2007-08-30 Gantner David C Silicone Skin Adhesive Gels With Enhanced Adhesion To Plastic
US7267829B2 (en) 1998-07-07 2007-09-11 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US20070237812A1 (en) * 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20080014259A1 (en) * 2006-05-16 2008-01-17 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
US20080051490A1 (en) * 1999-03-25 2008-02-28 Williams Simon F Medical Devices and Applications of Polyhydroxyalkanoate Polymers
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20080081071A1 (en) * 2006-09-29 2008-04-03 Pradeep Sanghvi Film Embedded Packaging and Method of Making Same
US20080085972A1 (en) * 2006-10-05 2008-04-10 O'brien Emmett Patrick Switchable adhesive article for attachment to skin and method of using the same
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20080132602A1 (en) * 2006-12-01 2008-06-05 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US20080160065A1 (en) * 2006-07-12 2008-07-03 Janet Anne Halliday Drug delivery polymer with hydrochloride salt of clindamycin
US20080227985A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazoles
US20080260809A1 (en) * 2002-04-11 2008-10-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20080260653A1 (en) * 2004-05-06 2008-10-23 Buttar Rashid A Transdermal Delivery Systems and Transdermal Chelation Preparations
US20090042956A1 (en) * 2006-04-10 2009-02-12 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US20090054504A1 (en) * 2006-12-14 2009-02-26 Knopp Neurosciences, Inc. Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same
US20090076542A1 (en) * 2004-02-18 2009-03-19 Jerry Jonn Adhesive-Containing Wound Closure Device And Method
US20090098069A1 (en) * 2007-09-14 2009-04-16 Drugtech Corporation Transdermal, alcohol-free, pharmaceutical compositions
US20090196911A1 (en) * 2006-06-06 2009-08-06 Loubert Gary L Silicone Acrylate Hybride Composition and Method Of Making Same
US20090286246A1 (en) * 2008-05-07 2009-11-19 Wintherix Llc Methods for Identifying Compounds that Affect Expression of Cancer-Related Protein Isoforms
US20090291120A1 (en) * 2006-07-05 2009-11-26 Jukka Tuominen Hydrophilic Polyurethane Compositions
US20090324692A1 (en) * 2006-07-08 2009-12-31 Controlled Therapeutics (Scotland) Limited Polyurethane Elastomers
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US20100055437A1 (en) * 2008-08-28 2010-03-04 Tyco Healthcare Group Lp Anti-microbial fibers and related articles and methods
US20100068708A1 (en) * 2008-05-07 2010-03-18 Wintherix Llc Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells
US20100121304A1 (en) * 2008-11-10 2010-05-13 Kimberly-Clark Worldwide, Inc. Multifunctional Acrylate Skin-Adhesive Composition
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US20110033541A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20110091488A1 (en) * 2002-09-27 2011-04-21 Controlled Therapeutics (Scotland) Limited Water-swellable polymers
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
DE102010053792A1 (en) 2010-12-08 2012-06-14 Frank Becher Device for germ-free keeping of surfaces, such as door handles, handrails, grip bars, handles of shopping carts and toilet seating surfaces, has flat support material and self-adhesive portion formed on one side of flat support material
WO2012094638A1 (en) 2011-01-07 2012-07-12 Skinmedica, Inc. Melanin modification compositions and methods of use
EP2584016A1 (en) 2011-10-21 2013-04-24 Dow Corning Corporation Single phase silicone acrylate formulation
EP2599847A1 (en) 2011-11-29 2013-06-05 Dow Corning Corporation A Silicone Acrylate Hybrid Composition and Method of Making Same
US8460707B2 (en) 2004-08-05 2013-06-11 Ferring B.V. Stabilised prostaglandin composition
DE102013202928A1 (en) 2012-02-23 2013-08-29 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
US8524254B2 (en) 2006-10-18 2013-09-03 Ferring B.V. Bioresorbable polymers
EP2650294A1 (en) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US8569416B2 (en) 2006-06-06 2013-10-29 Dow Corning Corporation Single phase silicone acrylate formulation
US8614278B2 (en) 2006-06-06 2013-12-24 Dow Corning Corporation Silicone acrylate hybrid composition and method of making same
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
DE102013107024A1 (en) 2011-11-15 2014-05-15 Golden Biotechnology Corporation Methods and compositions for treating, modifying and handling of bone cancer pain
DE102013107025A1 (en) 2011-12-30 2014-07-03 Golden Biotechnology Corporation Methods and compositions for behanldung of diabetis
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
WO2014130619A2 (en) 2013-02-20 2014-08-28 Golden Biotechnology Corporation Methods and compositions for treating leukemia
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9072636B2 (en) 2007-08-03 2015-07-07 Kimberly-Clark Worldwide, Inc. Dynamic fitting body adhering absorbent article
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9480770B2 (en) 2002-10-23 2016-11-01 Covidien Lp Methods for preparation of medical dressing containing antimicrobial agent
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9555155B2 (en) 2014-12-11 2017-01-31 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
US9700522B2 (en) 2007-03-19 2017-07-11 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US9814632B2 (en) 2007-08-03 2017-11-14 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US9820892B2 (en) 2007-08-03 2017-11-21 Kimberly-Clark Worldwide, Inc. Packaged body adhering absorbent article
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9895274B2 (en) 2007-12-28 2018-02-20 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) * 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
US3444858A (en) * 1965-05-14 1969-05-20 Higham S Russell Method and means for administering drugs
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3551556A (en) * 1966-01-06 1970-12-29 Ceskoslovenska Akademie Ved Carriers for biologically active substances
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3632740A (en) * 1968-06-13 1972-01-04 Johnson & Johnson Topical device for the therapeutic management of dermatological lesions with steroids

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) * 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
US3444858A (en) * 1965-05-14 1969-05-20 Higham S Russell Method and means for administering drugs
US3551556A (en) * 1966-01-06 1970-12-29 Ceskoslovenska Akademie Ved Carriers for biologically active substances
US3632740A (en) * 1968-06-13 1972-01-04 Johnson & Johnson Topical device for the therapeutic management of dermatological lesions with steroids
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122B1 (en) * 1969-04-01 1982-11-23

Cited By (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870041A (en) * 1973-08-16 1975-03-11 Btr Industries Ltd Surgical dressings
US3900027A (en) * 1974-01-02 1975-08-19 Pall Corp Process for preparing integral absorbent pad bandages and product
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
FR2368962A1 (en) * 1976-11-02 1978-05-26 Merck Patent Gmbh anti-bacterial dressing and process for its manufacture
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4340043A (en) * 1978-11-17 1982-07-20 Smith & Nephew Research Ltd. Adhesive-coated sheet material incorporating anti-bacterial substances
US4460369A (en) * 1978-11-17 1984-07-17 Smith & Nephew Research Ltd. Adhesive-coated sheet material incorporating anti-bacterial substances
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4455146A (en) * 1979-04-03 1984-06-19 Hisamitsu Pharmaceutical Co., Ltd. Novel plasters
US4226232A (en) * 1979-04-09 1980-10-07 Spenco Medical Corporation Wound dressing
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4292302A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing terbutaline
US4294820A (en) * 1979-08-14 1981-10-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylephrine
US4321252A (en) * 1979-08-14 1982-03-23 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ester derivatives of estradiol
US4492685A (en) * 1979-08-14 1985-01-08 Key Pharmaceuticals, Inc. Protective skin matrix
US4289749A (en) * 1979-08-14 1981-09-15 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylpropanolamine
US4292303A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing clonidine
US4292301A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ephedrine
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
US4390520A (en) * 1980-10-30 1983-06-28 Nitto Electric Industrial Co., Ltd. Antiphlogistic analgesic adhesive
US4329333A (en) * 1980-11-24 1982-05-11 Arthur Barr Method for the oral treatment of dogs and other animals
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4485087A (en) * 1981-03-13 1984-11-27 Nitto Electric Industrial Co., Ltd. Process for obtaining composite pharmaceutical preparation
DE3208853A1 (en) * 1981-03-13 1982-09-23 Nitto Electric Ind Co A process for the preparation of a pharmaceutical preparation composite
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
US4594240A (en) * 1982-09-10 1986-06-10 Teikoku Seiyaku Kabushiki Kaisha Sheet-shape adhesive preparation
US4767787A (en) * 1982-09-10 1988-08-30 Kaken Pharmaceutical Co., Ltd. Sheet-shape adhesive preparation
US4631227A (en) * 1982-12-08 1986-12-23 Kenji Nakamura Toilet article
US4532937A (en) * 1982-12-28 1985-08-06 Cuderm Corporation Sebum collection and monitoring means and method
WO1984002460A1 (en) * 1982-12-28 1984-07-05 Dermatec Ltd Sebum collection and monitoring means
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
USRE35474E (en) * 1984-10-29 1997-03-11 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4614787A (en) * 1984-11-13 1986-09-30 Thermedics, Inc. Drug dispensing wound dressing
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US4880690A (en) * 1984-11-13 1989-11-14 Thermedics, Inc. Perfume patch
US4751133A (en) * 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US4727868A (en) * 1984-11-13 1988-03-01 Thermedics, Inc. Anisotropic wound dressing
USRE32991E (en) * 1984-11-13 1989-07-18 Thermedics, Inc. Drug dispensing wound dressing
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
WO1987000042A1 (en) * 1985-07-02 1987-01-15 Rutgers, The State University Of New Jersey Transdermal verapamil delivery device
WO1987003477A1 (en) * 1985-12-12 1987-06-18 Flexcon Company, Inc. Transdermal methods and adhesives
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US5034386A (en) * 1986-01-31 1991-07-23 Whitby Research, Inc. Methods for administration using 1-substituted azacycloalkanes
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
EP0236266A1 (en) * 1986-02-14 1987-09-09 Ciba-Geigy Ag Dermal and transdermal therapeutic system having a discontinuous-pattern adhesive layer and method of manufacturing thereof
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6117448A (en) * 1986-08-28 2000-09-12 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6224900B1 (en) 1986-08-28 2001-05-01 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Sealing bag for a transdermal therapeutic system
US5820876A (en) * 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
US6264977B1 (en) 1986-08-28 2001-07-24 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
USRE37934E1 (en) 1986-08-28 2002-12-10 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
US6126963A (en) * 1986-08-28 2000-10-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
DE3629304A1 (en) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg A transdermal therapeutic system, its use and process for its manufacture
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US4889720A (en) * 1986-09-01 1989-12-26 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form for use with tissues of the oral cavity
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5342623A (en) * 1986-09-12 1994-08-30 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US4844903A (en) * 1986-11-07 1989-07-04 Mepha Ag Process for the production of an adhesive plaster
EP0273004A3 (en) * 1986-11-20 1988-07-13 Ciba-Geigy Ag User-activated therapeutical system
EP0273004A2 (en) * 1986-11-20 1988-06-29 Ciba-Geigy Ag User-activated therapeutical system
US5298257A (en) * 1987-05-01 1994-03-29 Elan Transdermal Limited Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method
US4991574A (en) * 1987-07-22 1991-02-12 Dow Corning Corporation Surgical dressing
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US5035894A (en) * 1987-10-15 1991-07-30 Dow Corning Corporation Controlled release compositions and transdermal drug delivery device
USRE39588E1 (en) 1987-11-09 2007-04-24 Alza Corporation Transdermal drug delivery device
WO1989005582A1 (en) * 1987-12-18 1989-06-29 Russell Isaac Copelan Chemical splinter removal
US4830854A (en) * 1987-12-18 1989-05-16 James B. Copelan Chemical splinter removal
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US5633008A (en) * 1988-06-14 1997-05-27 Osborne; James L. Method of administering nicotine transdermally
US6165497A (en) * 1988-06-14 2000-12-26 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US4985016A (en) * 1989-02-15 1991-01-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4969871A (en) * 1989-02-15 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent
US5250028A (en) * 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US5045059A (en) * 1989-02-15 1991-09-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5160320A (en) * 1989-02-15 1992-11-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5176915A (en) * 1989-03-14 1993-01-05 Lts Lohmann Plaster used as therapeutic system for the administration of active substances to the skin which exhibits a graduated active substance release, process for the production of the plaster and the use thereof
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5230896A (en) * 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
US5173302A (en) * 1990-09-28 1992-12-22 Medtronic, Inc. Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
US5837280A (en) * 1990-11-28 1998-11-17 Sano Corporation Transdermal administration of azapirones
US5817331A (en) * 1990-11-28 1998-10-06 Sano Corporation Transdermal administration of azapirones
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5508039A (en) * 1991-10-18 1996-04-16 Alza Corporation Controlled transdermal administration of melatonin
US6300327B1 (en) 1991-11-08 2001-10-09 The University Of Southern California Compositions and methods for potentiation of neurotrophin activity
US5268179A (en) * 1992-02-14 1993-12-07 Ciba-Geigy Corporation Ultrasonically sealed transdermal drug delivery systems
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5919478A (en) * 1993-06-25 1999-07-06 Alza Corporation Incorporating poly-N-vinyl amide in a transdermal system
US5747065A (en) * 1993-09-29 1998-05-05 Lee; Eun Soo Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5750137A (en) * 1993-09-29 1998-05-12 Taskovich; Lina Tormen Monoglyceride/lactate ester permeation enhancer
US5643596A (en) * 1993-11-03 1997-07-01 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5645849A (en) * 1993-11-03 1997-07-08 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5741510A (en) * 1994-03-30 1998-04-21 Lectec Corporation Adhesive patch for applying analgesic medication to the skin
US6096334A (en) * 1994-03-30 2000-08-01 Lectec Corporation Adhesive patch for applying medication to the skin and method
US6096333A (en) * 1994-03-30 2000-08-01 Lectec Corporation Method of forming adhesive patch for applying medication to the skin
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US20040209909A1 (en) * 1995-06-07 2004-10-21 Su Il Yum Novel formulations for transdermal delivery of pergolide
US5843468A (en) * 1995-06-07 1998-12-01 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US6001390A (en) * 1995-06-07 1999-12-14 Alza Corporation Formulations for transdermal delivery of pergolide
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
EP1674068A1 (en) 1996-02-19 2006-06-28 Acrux DDS Pty Ltd Dermal penetration enhancers and drug delivery systems involving same
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US20050186277A1 (en) * 1996-07-15 2005-08-25 Gale Robert M. Novel formulations for the administration of fluoxetine
US7011844B2 (en) 1996-07-15 2006-03-14 Alza Corporation Formulations for the administration of fluoxetine
US6479073B1 (en) * 1996-10-07 2002-11-12 3M Innovative Properties Company Pressure sensitive adhesive articles and methods for preparing same
US20040137047A1 (en) * 1996-10-07 2004-07-15 3M Innovative Properties Company Pressure sensitive adhesive articles and methods for preparing same
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
EP1399145A4 (en) * 1998-02-12 2004-08-18 Watson Pharmaceuticals Inc Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
WO1999040955A2 (en) * 1998-02-12 1999-08-19 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
EP1399145A2 (en) * 1998-02-12 2004-03-24 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US6727401B1 (en) 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US7267829B2 (en) 1998-07-07 2007-09-11 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US6960353B2 (en) 1998-07-24 2005-11-01 Alza Corporation Formulations for the transdermal administration of fenoldopam
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
EP2158903A2 (en) 1998-12-18 2010-03-03 ALZA Corporation Transparent Transdermal Nicotine Delivery Devices
US20040234585A1 (en) * 1998-12-18 2004-11-25 Gale Robert M. Transparent transdermal nicotine delivery devices
US8075911B2 (en) 1998-12-18 2011-12-13 Alza Corporation Transparent transdermal nicotine delivery devices
US9205059B2 (en) 1998-12-18 2015-12-08 Alza Corporation Transparent transdermal nicotine delivery devices
US7622136B2 (en) 1998-12-18 2009-11-24 Alza Corporation Transparent transdermal nicotine delivery devices
US20080031933A1 (en) * 1998-12-18 2008-02-07 Alza Corporation Transparent transdermal nicotine delivery devices
US8999379B2 (en) 1998-12-18 2015-04-07 Alza Corporation Transparent transdermal nicotine delivery devices
US8663680B2 (en) 1998-12-18 2014-03-04 Alza Corporation Transparent transdermal nicotine delivery devices
US7553923B2 (en) 1999-03-25 2009-06-30 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US20080095823A1 (en) * 1999-03-25 2008-04-24 Metabolix, Inc. Medical Devices and Applications of Polyhydroxyalkanoate Polymers
US20080051490A1 (en) * 1999-03-25 2008-02-28 Williams Simon F Medical Devices and Applications of Polyhydroxyalkanoate Polymers
US20050048104A1 (en) * 1999-04-01 2005-03-03 Venkatraman Subramanian S. Transdermal drug delivery devices comprising a polyurethane drug reservoir
US6183770B1 (en) * 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6261593B1 (en) 1999-04-15 2001-07-17 Acutek International Carrier patch for the delivery of agents to the skin
US6592892B1 (en) 1999-08-30 2003-07-15 Tepha, Inc. Flushable disposable polymeric products
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6469227B1 (en) 1999-12-10 2002-10-22 Lectec Corporation Antipruritic patch
US20060121103A1 (en) * 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US8685437B2 (en) 2001-10-12 2014-04-01 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20030107149A1 (en) * 2001-10-12 2003-06-12 International Fluidics. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070069416A1 (en) * 2001-10-12 2007-03-29 Monosolrx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US7824588B2 (en) 2001-10-12 2010-11-02 Monosol Rx, Llc Method of making self-supporting therapeutic active-containing film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US20070122455A1 (en) * 2001-10-12 2007-05-31 Monosolrx, Llc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070149731A1 (en) * 2001-10-12 2007-06-28 Monosolrx, Llc. PH modulated films for delivery of actives
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20090181069A1 (en) * 2001-10-12 2009-07-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20080260805A1 (en) * 2001-10-12 2008-10-23 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20050184427A1 (en) * 2001-10-12 2005-08-25 Monosolrx, Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) * 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20080044454A1 (en) * 2002-04-11 2008-02-21 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20050037055A1 (en) * 2002-04-11 2005-02-17 Monosolrx Llc. Polyethylene oxide-based films and drug delivery systems made therefrom
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20080260809A1 (en) * 2002-04-11 2008-10-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20060147493A1 (en) * 2002-07-22 2006-07-06 Yang Robert K Packaging and dispensing of rapid dissolve dosage form
US20110091488A1 (en) * 2002-09-27 2011-04-21 Controlled Therapeutics (Scotland) Limited Water-swellable polymers
US8557281B2 (en) 2002-09-27 2013-10-15 Ferring B.V. Water-swellable polymers
US8628798B2 (en) 2002-09-27 2014-01-14 Ferring B.V. Water-swellable polymers
US9480770B2 (en) 2002-10-23 2016-11-01 Covidien Lp Methods for preparation of medical dressing containing antimicrobial agent
US20040209907A1 (en) * 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US20050002997A1 (en) * 2003-04-30 2005-01-06 Howard Stephen A. Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8758657B2 (en) 2003-05-08 2014-06-24 Tepha, Inc. Process of making polyhydroxyalkanoate medical textiles
US20040234576A1 (en) * 2003-05-08 2004-11-25 Tepha, Inc., State Of Incorporation Delaware Polyhydroxyalkanoate medical textiles and fibers
US9333066B2 (en) 2003-05-08 2016-05-10 Tepha, Inc. Method of making a medical textile from polyhydroxyalkanoate fibers
US9125719B2 (en) 2003-05-08 2015-09-08 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
US8034270B2 (en) 2003-05-08 2011-10-11 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US20050025809A1 (en) * 2003-07-08 2005-02-03 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
US20060287659A1 (en) * 2003-08-22 2006-12-21 Tepha, Inc. Polyhydroxyalkanoate nerve regeneration devices
US20090209983A1 (en) * 2003-08-22 2009-08-20 Tepha, Inc. Polyhydroxyalkanoate nerve regeneration devices
US20050065062A1 (en) * 2003-09-24 2005-03-24 3M Innovative Properties Company Method of formulating a pharmaceutical composition
US20050142475A1 (en) * 2003-12-30 2005-06-30 Moudry Ronald J. Dry toner comprising encapsulated pigment, methods and uses
US9655622B2 (en) 2004-02-18 2017-05-23 Ethicon, Inc. Adhesive-containing wound closure device and method
US20090076542A1 (en) * 2004-02-18 2009-03-19 Jerry Jonn Adhesive-Containing Wound Closure Device And Method
US20070202245A1 (en) * 2004-04-08 2007-08-30 Gantner David C Silicone Skin Adhesive Gels With Enhanced Adhesion To Plastic
US20080260653A1 (en) * 2004-05-06 2008-10-23 Buttar Rashid A Transdermal Delivery Systems and Transdermal Chelation Preparations
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US20060009099A1 (en) * 2004-07-12 2006-01-12 Closure Medical Corporation Adhesive-containing wound closure device and method
US20080255610A1 (en) * 2004-07-12 2008-10-16 Closure Medical Corporation Adhesive-Containing Wound Closure Device and Method
US9623142B2 (en) 2004-07-12 2017-04-18 Ethicon, Inc. Adhesive-containing wound closure device and method
US20060058470A1 (en) * 2004-08-03 2006-03-16 Tepha, Inc. Non-curling polyhydroxyalkanoate sutures
US7641825B2 (en) 2004-08-03 2010-01-05 Tepha, Inc. Method of making a polyhydroxyalkanoate filament
US20100093237A1 (en) * 2004-08-03 2010-04-15 Tepha, Inc. Non-curling polyhydroxyalkanoate sutures
US8084125B2 (en) 2004-08-03 2011-12-27 Tepha, Inc. Non-curling polyhydroxyalkanoate sutures
US8709482B2 (en) 2004-08-05 2014-04-29 Ferring B.V. Stabilised prostaglandin composition
US8460707B2 (en) 2004-08-05 2013-06-11 Ferring B.V. Stabilised prostaglandin composition
US8491934B2 (en) 2004-08-05 2013-07-23 Ferring B.V. Stabilised prostaglandin composition
WO2007011763A3 (en) * 2005-07-15 2007-07-12 3M Innovative Properties Co Adhesive sheet and methods of use thereof
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9198939B2 (en) 2005-09-27 2015-12-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9161956B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US20070231401A1 (en) * 2005-09-27 2007-10-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9161955B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US9750772B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20080299087A1 (en) * 2005-09-27 2008-12-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8440235B2 (en) 2005-09-27 2013-05-14 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
EP2664337A1 (en) 2005-09-27 2013-11-20 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US9724370B2 (en) 2005-09-27 2017-08-08 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9750771B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8455009B2 (en) 2005-09-27 2013-06-04 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9956252B2 (en) 2005-09-27 2018-05-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8460714B2 (en) 2005-09-27 2013-06-11 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8182841B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9161954B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8420126B2 (en) 2005-09-27 2013-04-16 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US20090042956A1 (en) * 2006-04-10 2009-02-12 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US20070237812A1 (en) * 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
US20080014259A1 (en) * 2006-05-16 2008-01-17 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same
US8017598B2 (en) 2006-05-16 2011-09-13 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
US8445474B2 (en) 2006-05-16 2013-05-21 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
US20090196911A1 (en) * 2006-06-06 2009-08-06 Loubert Gary L Silicone Acrylate Hybride Composition and Method Of Making Same
US8614278B2 (en) 2006-06-06 2013-12-24 Dow Corning Corporation Silicone acrylate hybrid composition and method of making same
US8569416B2 (en) 2006-06-06 2013-10-29 Dow Corning Corporation Single phase silicone acrylate formulation
US8124689B2 (en) 2006-06-06 2012-02-28 Dow Corning Corporation Silicone acrylate hybride composition and method of making same
US20090291120A1 (en) * 2006-07-05 2009-11-26 Jukka Tuominen Hydrophilic Polyurethane Compositions
US8974813B2 (en) 2006-07-05 2015-03-10 Ferring B.V. Hydrophilic polyurethane compositions
US8361272B2 (en) 2006-07-08 2013-01-29 Ferring B.V. Polyurethane elastomers
US8361273B2 (en) 2006-07-08 2013-01-29 Ferring B.V. Polyurethane elastomers
US20090324692A1 (en) * 2006-07-08 2009-12-31 Controlled Therapeutics (Scotland) Limited Polyurethane Elastomers
US20080160065A1 (en) * 2006-07-12 2008-07-03 Janet Anne Halliday Drug delivery polymer with hydrochloride salt of clindamycin
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US7972618B2 (en) 2006-09-20 2011-07-05 Monosol Rx, Llc Edible water-soluble film containing a foam reducing flavoring agent
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
EP2529622A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2532234A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2530083A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526933A2 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526934A2 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2201840A1 (en) 2006-09-22 2010-06-30 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526771A1 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2529621A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2443929A1 (en) 2006-09-22 2012-04-25 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US20080081071A1 (en) * 2006-09-29 2008-04-03 Pradeep Sanghvi Film Embedded Packaging and Method of Making Same
US7879942B2 (en) 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
US20080085972A1 (en) * 2006-10-05 2008-04-10 O'brien Emmett Patrick Switchable adhesive article for attachment to skin and method of using the same
US8524254B2 (en) 2006-10-18 2013-09-03 Ferring B.V. Bioresorbable polymers
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US20080132602A1 (en) * 2006-12-01 2008-06-05 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US8753555B2 (en) 2006-12-01 2014-06-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US20110189475A1 (en) * 2006-12-01 2011-08-04 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
US20090054504A1 (en) * 2006-12-14 2009-02-26 Knopp Neurosciences, Inc. Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20080227985A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazoles
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US9700522B2 (en) 2007-03-19 2017-07-11 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US9820892B2 (en) 2007-08-03 2017-11-21 Kimberly-Clark Worldwide, Inc. Packaged body adhering absorbent article
US9072636B2 (en) 2007-08-03 2015-07-07 Kimberly-Clark Worldwide, Inc. Dynamic fitting body adhering absorbent article
US9814632B2 (en) 2007-08-03 2017-11-14 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US20090098069A1 (en) * 2007-09-14 2009-04-16 Drugtech Corporation Transdermal, alcohol-free, pharmaceutical compositions
US9895274B2 (en) 2007-12-28 2018-02-20 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US20090286246A1 (en) * 2008-05-07 2009-11-19 Wintherix Llc Methods for Identifying Compounds that Affect Expression of Cancer-Related Protein Isoforms
US20100068708A1 (en) * 2008-05-07 2010-03-18 Wintherix Llc Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US9849116B2 (en) 2008-08-19 2017-12-26 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
US20100055437A1 (en) * 2008-08-28 2010-03-04 Tyco Healthcare Group Lp Anti-microbial fibers and related articles and methods
US20100121304A1 (en) * 2008-11-10 2010-05-13 Kimberly-Clark Worldwide, Inc. Multifunctional Acrylate Skin-Adhesive Composition
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US20110033541A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9687454B2 (en) 2009-08-07 2017-06-27 Indivior Uk Limited Sublingual and buccal film compositions
EP2650294A1 (en) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
US9212151B2 (en) 2010-03-24 2015-12-15 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US9550822B2 (en) 2010-10-25 2017-01-24 Questcor Pharmaceuticals, Inc. ACTH prophylactic treatment of renal disorders
DE102010053792A1 (en) 2010-12-08 2012-06-14 Frank Becher Device for germ-free keeping of surfaces, such as door handles, handrails, grip bars, handles of shopping carts and toilet seating surfaces, has flat support material and self-adhesive portion formed on one side of flat support material
WO2012094638A1 (en) 2011-01-07 2012-07-12 Skinmedica, Inc. Melanin modification compositions and methods of use
US8778315B2 (en) 2011-01-07 2014-07-15 Allergan, Inc. Melanin modification compositions and methods of use
US8236288B2 (en) 2011-01-07 2012-08-07 Skinmedica, Inc. Melanin modification compositions and methods of use
US9044404B2 (en) 2011-01-07 2015-06-02 Allergan, Inc. Melanin modification compositions and methods of use
US9675733B2 (en) 2011-04-28 2017-06-13 Tissuetech, Inc. Methods of modulating bone remodeling
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
EP2584016A1 (en) 2011-10-21 2013-04-24 Dow Corning Corporation Single phase silicone acrylate formulation
DE102013107024A1 (en) 2011-11-15 2014-05-15 Golden Biotechnology Corporation Methods and compositions for treating, modifying and handling of bone cancer pain
EP2599847A1 (en) 2011-11-29 2013-06-05 Dow Corning Corporation A Silicone Acrylate Hybrid Composition and Method of Making Same
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DE102013107025A1 (en) 2011-12-30 2014-07-03 Golden Biotechnology Corporation Methods and compositions for behanldung of diabetis
DE102013202928A1 (en) 2012-02-23 2013-08-29 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014130619A2 (en) 2013-02-20 2014-08-28 Golden Biotechnology Corporation Methods and compositions for treating leukemia
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9956206B2 (en) 2013-02-28 2018-05-01 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9968586B2 (en) 2014-02-10 2018-05-15 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9707206B2 (en) 2014-02-10 2017-07-18 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9555155B2 (en) 2014-12-11 2017-01-31 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase

Similar Documents

Publication Publication Date Title
US3632740A (en) Topical device for the therapeutic management of dermatological lesions with steroids
US5059189A (en) Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US4725272A (en) Novel bandage for administering beneficial drug
US5662925A (en) Transdermal delivery system with adhesive overlay and peel seal disc
US7579019B2 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US5679373A (en) Process of assembling a transdermal patch incorporating a polymer film incorporated with an active agent
US5082663A (en) External adhesive preparation containing steroids
US4818540A (en) Transdermal fertility control system and process
US6153215A (en) Dressing for dosing one or more medicaments
US4031894A (en) Bandage for transdermally administering scopolamine to prevent nausea
US5641504A (en) Skin permeation enhancer compositions using glycerol monolinoleate
US5227169A (en) Sorbitan esters as skin permeation enhancers
US5154922A (en) Compositions for transdermal delivery of estradiol
US4698062A (en) Medical device for pulsatile transdermal delivery of biologically active agents
US5122383A (en) Sorbitan esters as skin permeation enhancers
US4675009A (en) Drug dispensing device for transdermal delivery of medicaments
US6682757B1 (en) Titratable dosage transdermal delivery system
US6893655B2 (en) Transdermal delivery devices
US6465004B1 (en) Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US4784857A (en) Drug delivery device, its preparation and use
US4262003A (en) Method and therapeutic system for administering scopolamine transdermally
US5049387A (en) Inducing skin tolerance to a sensitizing drug
US20030170195A1 (en) Compositions and methods for drug delivery
US3598123A (en) Bandage for administering drugs
US7063859B1 (en) Barrier film lined backing layer composition and method for topical administration of active agents